Trials / Completed
CompletedNCT00266526
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Allergopharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant birch pollen |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2004-07-01
- Completion
- 2005-07-01
- First posted
- 2005-12-19
- Last updated
- 2013-03-04
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00266526. Inclusion in this directory is not an endorsement.